intellectual property / patents

Cytopia has a strong and growing intellectual property platform based on:

Targets
Exclusive worldwide license to several granted patents on validated drug targets-JAK1 and JAK2 kinases.

Mechanisms
A family of patent applications on a novel mechanism of kinase inhibition.

Novel chemicals
A suite of patent applications claiming novel kinase and tubulin inhibitors as new chemical entities. A number of these applications have resulted in issued or granted patents in countries such as the U.S.A & the U.K.

Applications

• Patent applications covering kinase inhibitor design and selection.
• Patent applications for a new use of kinase inhibitors for the treatment of diseases.

Techniques
Proprietary software platform - ChemaPhore for in silico drug design and screening.